{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.470","upperLimit":"0.660","value":"0.566"},{"groupId":"OG001","lowerLimit":"0.231","upperLimit":"0.484","value":"0.350"},{"groupId":"OG002","lowerLimit":"0.278","upperLimit":"0.770","value":"0.529"},{"groupId":"OG003","lowerLimit":"0.232","upperLimit":"0.655","value":"0.435"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"113"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"23"}],"units":"Participants"}],"description":"Objective tumour response rate (OTRR) is defined as the proportion of participants with a documented complete response, partial response (CR + PR) based on iRECIST criteria.","dispersionType":"95% Confidence Interval","groups":[{"description":"Durvalumab + Standard Chemotherapy for 4 to 6 cycles, followed by Maintenance with Durvalumab\n\nDurvalumab: Durvalumab 1500 milligrams (mg) intravenous (IV) every 3 weeks + Cisplatin 75 mg/m² or Carboplatin AUC 5 IV every 3 weeks + Pemetrexed 500 mg/m² IV every 3 weeks for 4 to 6 cycles, followed by maintenance with Durvalumab 1500 mg IV every 4 weeks","id":"OG000","title":"Experimental Arm for Chemo Cohort: Durvalumab + Chemotherapy, Then Durvalumab Maintenance"},{"description":"Standard Chemotherapy for 4 to 6 cycles, followed by Observation\n\nStandard Chemotherapy: Cisplatin 75 mg/m² or Carboplatin AUC 5 IV every 3 weeks + Pemetrexed 500 mg/m² IV every 3 weeks) for 4 to 6 cycles, followed by Observation","id":"OG001","title":"Control Arm for Chemo Cohort: Chemotherapy, Then Observation"},{"description":"Durvalumab + Standard Chemotherapy for 4 to 6 cycles, followed by Maintenance with Durvalumab\n\nDurvalumab: Durvalumab 1500 milligrams (mg) intravenous (IV) every 3 weeks + Cisplatin 75 mg/m² or Carboplatin AUC 5 IV every 3 weeks + Pemetrexed 500 mg/m² IV every 3 weeks for 4 to 6 cycles, followed by maintenance with Durvalumab 1500 mg IV every 4 weeks","id":"OG002","title":"Experimental Arm for IO Cohort: Durvalumab + Chemotherapy, Then Durvalumab Maintenance"},{"description":"Ipilimumab every 6 weeks and Nivolumab every 2 or 3 weeks for up to 2 years.\n\nIpilimumab and Nivolumab: Ipilimumab 1 mg/kg every 6 weeks and Nivolumab 360 mg every 3 weeks or 3 mg/kg every 2 weeks for up to 2 years","id":"OG003","title":"Control Arm for IO Cohort: Ipilimumab and Nivolumab"}],"paramType":"NUMBER","populationDescription":"The analysis population is comprised of intention-to-treat patients. One patient in the experimental arm of the Chemo Cohort was excluded due to a randomization error, with no treatment or follow-up data available.","reportingStatus":"POSTED","timeFrame":"Disease was evaluated at baseline, then at weeks 6, 12, 18, 26, 34, 42, 50 and then every 12 weeks until disease progression (minimum follow-up is 24 months after randomisation). The treatment duration ranged from 0 to 36 months.","title":"Objective Tumour Response Rate (OTRR)","type":"SECONDARY","unitOfMeasure":"proportion of participants"}